Tourmaline Bio Inc
NASDAQ:TRML
Relative Value
There is not enough data to reliably calculate the relative value of TRML.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
TRML Competitors Multiples
Tourmaline Bio Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Tourmaline Bio Inc
NASDAQ:TRML
|
599.6m USD | 0 | -14.2 | -8.7 | -8.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
290.3B USD | 5.3 | 60.2 | 13.1 | 19.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
168.9B USD | 5.7 | 44.9 | 18.9 | 31.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD | 11.5 | 31.3 | 25.3 | 26.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.7B USD | 8.1 | 27.7 | 22.4 | 24.8 | ||
AU |
CSL Ltd
ASX:CSL
|
138.6B AUD | 6.6 | 37.6 | 22.6 | 28.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | 174.7 | 7 | 9.2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
50.9B USD | 9.9 | -8.5 | -9.4 | -8.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 3.5 | 28.7 | 14.6 | 18.3 | ||
KR |
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.7 | 45.7 | 62.9 |